Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce F Liu

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Clinical Advances in Hematology & Oncology : H&O|October 6, 2025
The use of antibody-drug conjugates in gynecologic cancersJoyce F Liu
Gynecologic Oncology|August 11, 2020
Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical OncologyRitu Salani, Joyce F Liu
Gynecologic Oncology|July 2, 2021
The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstractsRitu Salani, Joyce F Liu
Current Opinion in Oncology|August 27, 2010
Poly ADP-ribose polymerase inhibitors: science and current clinical developmentJoyce F Liu, Daniel P Silver
Clinical Advances in Hematology & Oncology : H&O|August 7, 2024
Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapiesElizabeth K Lee, Joyce F Liu
Current Oncology Reports|March 18, 2016
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?Joyce F Liu, Ursula A Matulonis
Cancer Treatment and Research|November 17, 2023
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted AgentsElizabeth K Lee, Joyce F Liu
Gynecologic Oncology|April 2, 2019
Antibody-drug conjugates in gynecologic malignanciesElizabeth K Lee, Joyce F Liu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2023
Treatment Approaches for Platinum-Resistant Ovarian CancerJessica St Laurent, Joyce F Liu
The Lancet. Oncology|June 28, 2015
Bevacizumab in newly diagnosed ovarian cancerJoyce F Liu, Ursula A Matulonis
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Clinical Advances in Hematology & Oncology : H&O|October 6, 2025
The use of antibody-drug conjugates in gynecologic cancersJoyce F Liu
Gynecologic Oncology|August 11, 2020
Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical OncologyRitu Salani, Joyce F Liu
Gynecologic Oncology|July 2, 2021
The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstractsRitu Salani, Joyce F Liu
Current Opinion in Oncology|August 27, 2010
Poly ADP-ribose polymerase inhibitors: science and current clinical developmentJoyce F Liu, Daniel P Silver
Clinical Advances in Hematology & Oncology : H&O|August 7, 2024
Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapiesElizabeth K Lee, Joyce F Liu
Current Oncology Reports|March 18, 2016
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?Joyce F Liu, Ursula A Matulonis
Cancer Treatment and Research|November 17, 2023
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted AgentsElizabeth K Lee, Joyce F Liu
Gynecologic Oncology|April 2, 2019
Antibody-drug conjugates in gynecologic malignanciesElizabeth K Lee, Joyce F Liu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2023
Treatment Approaches for Platinum-Resistant Ovarian CancerJessica St Laurent, Joyce F Liu
The Lancet. Oncology|June 28, 2015
Bevacizumab in newly diagnosed ovarian cancerJoyce F Liu, Ursula A Matulonis
Pageof 11